Last reviewed · How we verify
NCT05417906
Using the Blood Eosinophil Count to Guide Systemic Corticosteroid Treatment in Asthma Exacerbations
Phase 2 trial testing Standard care in Asthma Attack in 110 participants. Participants enrolled and being followed up; not accepting new ones.
30 September 2025
Quick facts
| Lead sponsor | Changi General Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 110 |
| Start date | 2 June 2022 |
| Primary completion | 30 September 2025 |
| Estimated completion | 30 September 2026 |
| Sites | 2 locations across Singapore |
Drugs / interventions tested
- Standard care — full drug profile →
- Eosinophil-directed care
Conditions studied
- Asthma Attack — all drugs for Asthma Attack →
- Asthma — all drugs for Asthma →
Sponsor
Changi General Hospital
Who can join
21 and older, any sex, with Asthma Attack or Asthma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Asthma attacks which are moderate-to-severe are typically treated with corticosteroids, but the optimal treatment duration is unknown and treatment responses can be variable. Inadequate treatment may compromise recovery, but increased exposure to corticosteroids is, in turn, associated with drug-related adverse effects. There is a need for a biomarker to guide duration of corticosteroid treatment in asthma attacks. One such candidate biomarker is the blood eosinophil count, which may predict steroid-responsiveness. We hypothesize that the blood eosinophil count can potentially be used as a biomarker to guide the duration of corticosteroids in moderate-to-severe asthma attacks. This study will recruit individuals hospitalized for asthma attack. Participants will be randomized to standard care or blood-eosinophil guided systemic corticosteroid therapy. Subjects in the standard arm will receive oral corticosteroids for a total of 5 days. Subjects in the blood-eosinophil guided arm will receive oral corticosteroids for a total of 5 days if admission eosinophil count is ≥ 0.300 x 10\^3/µL, and receive 3 days of oral corticosteroids if the admission blood eosinophil is \< 0.300 x 10\^3/µL. The rate of treatment failure will be compared between these two groups.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Blood eosinophil-guided systemic corticosteroid duration in adults hospitalised for asthma exacerbation: a randomised, controlled, open-label, non-inferiority trial.
Yii A, Tay TR, Lee KCH, Chew SY, et al · · 2026 · cited 1× · PMID 41339088 · DOI 10.1136/thorax-2025-223961
Verify or expand the search:
- PubMed search for NCT05417906
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Standard care
Trials testing the same drug.
- NCT04980703 — Grain Moxibustion Treatment on Insomnia: a Randomized Controlled Trial · NA · not yet recruiting
- NCT07456280 — Evaluation of the Non-invasive Electrocardiographic Monitoring Strategy Associated With Early Discharge in Patients With · NA · not yet recruiting
- NCT07511868 — Digital Application for Stroke Health · NA · not yet recruiting
- NCT07383103 — Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock · Phase 4 · recruiting
- NCT07376668 — Effects of a WhatsApp-assisted Prehabilitation for Patient Undergoing Elective Colorectal Cancer Surgery · NA · not yet recruiting
Other recruiting trials for Asthma Attack
Currently open trials in the same condition.
- NCT07129616 — Remote Monitoring of Asthma in Children and Young People · recruiting
- NCT07052942 — Individualizing Treatment for Asthma in Primary Care (Full Study) · Phase 4 · recruiting
- NCT06734793 — Wearable Electronic Breath Sound Sensing Device · recruiting
- NCT06377345 — Remote Patient Monitoring Solution for Chronic Respiratory Disease Management · NA · recruiting
- NCT06137040 — Timely Administration of IV Magnesium Sulfate in Patients With a Moderate Asthma Exacerbation · EARLY_PHASE1 · recruiting
Other Changi General Hospital trials
Trials by the same sponsor.
- NCT07297745 — Trial of Aldosterone-hybrid SteRoid for Guiding curablE Treatment of Primary Aldosteronism (TARGET-PA) · NA · not yet recruiting
- NCT07205133 — A Randomized Controlled Trial Comparing Whole Body Vibration Therapy With Usual Care and Usual Care to Improve Muscle He · NA · recruiting
- NCT06970717 — Programmable Smart Watch for Remote Pre-habilitation/Rehabilitation Monitoring · NA · not yet recruiting
- NCT06890169 — OneSTOP (One-Stop Telehealth Obesity Program) for Multidisciplinary Weight Management and Related Comorbidities · NA · recruiting
- NCT06304415 — Elevated Lipoprotein(a) in Hospital Staff · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05417906 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Changi General Hospital
- Last refreshed: 21 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05417906.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing